Immunomodulator agents for HIV
Executive Summary
FDA's Antiviral Drugs Advisory Committee will meet Oct. 16 to discuss the use of surrogate markers in the early development of immunomodulator agents for the treatment of patients with HIV. The meeting will be held at the Marriot in Gaithersburg, Md. beginning at 8:30 a.m